Headspace vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Headspace is a mindfulness and mental health app offering guided meditation, sleep content, and enterprise employee wellbeing programs to over 70 million users.
About
Headspace is a mental wellness company founded in 2010 by Andy Puddicombe and Rich Pierson that has grown into one of the most widely used mindfulness and meditation apps globally. The platform offers guided meditation sessions, sleep content, stress reduction exercises, and mental fitness programs for both individual consumers and enterprise employees through its Headspace for Work product. Headspace merged with Ginger, a mental health coaching and therapy platform, in 2021 to form Headspace Health, expanding from mindfulness content into clinical mental health services. The combined platform provides a continuum from self-guided wellness content through human-delivered coaching and therapy, serving both consumers and employers who want comprehensive mental health benefits. Headspace for Work serves over 4,000 employer customers providing evidence-backed mental wellness programs to millions of employees globally. The company has published research demonstrating measurable improvements in stress, burnout, and resilience from Headspace use. Following the merger, Headspace has integrated its consumer brand recognition with Ginger's clinical platform to serve the full spectrum of mental health needs.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.